Atrasentan hydrochloride is under clinical development by Chinook Therapeutics and currently in Phase III for IgA Nephropathy (Berger’s Disease). According to GlobalData, Phase III drugs for IgA Nephropathy (Berger’s Disease) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Atrasentan hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Atrasentan hydrochloride overview
Atrasentan hydrochloride (ABT-627) is under development for the treatment of immunoglobulin A nephropathy and proteinuric glomerular diseases including focal segmental glomerulosclerosis (FSGS), alport syndrome and diabetic kidney disease (DKD). The drug candidate is administered orally. The drug candidate selectively targets endothelin-A receptor. It was also under development for the treatment of diabetic nephropathy associated with chronic kidney disease, pediatric nephrotic syndrome, metastatic hormone-refractory prostate cancer, hypertension, diabetic neuropathic pain and ovarian cancer
See Also:
Chinook Therapeutics overview
Chinook Therapeutics, Inc (Chinook)., formerly Aduro BioTech Inc is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. It’s pipeline products include atrasentan, Bion- 1301 for the treatment of IgA Nephropathy, CHK-336 for idiopathic hyperoxaluria, research and discovery programs for the treatment of rare, severe chronic kidney diseases among others. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sting pathway activators and B-select monoclonal antibodies to create immunotherapies for the treatment of cancers, infectious and autoimmune diseases. Its products are under development and are intended for the treatment of variety of cancers, including metastatic colorectal, multiple myeloma cancers, solid tumors and lymphomas. The company collaborates with various pharmaceutical companies to expand its products and technology platforms. It has an operational presence in The Netherlands. Chinook is headquartered in Berkeley, California, the US.
For a complete picture of Atrasentan hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
